vs
Side-by-side financial comparison of FinVolution Group (FINV) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $479.7M, roughly 1.0× FinVolution Group). FinVolution Group runs the higher net margin — 21.2% vs 6.8%, a 14.4% gap on every dollar of revenue.
Volution Group plc is a manufacturer of ventilation equipment for commercial and residential customers. Based in Crawley, West Sussex, the company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
FINV vs MD — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $479.7M | $493.8M |
| Net Profit | $101.7M | $33.7M |
| Gross Margin | — | — |
| Operating Margin | 44.6% | 9.9% |
| Net Margin | 21.2% | 6.8% |
| Revenue YoY | — | -1.7% |
| Net Profit YoY | — | 10.5% |
| EPS (diluted) | — | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $493.8M | ||
| Q3 25 | — | $492.9M | ||
| Q2 25 | — | $468.8M | ||
| Q1 25 | $479.7M | $458.4M | ||
| Q4 24 | — | $502.4M | ||
| Q3 24 | — | $511.2M | ||
| Q2 24 | — | $504.3M | ||
| Q1 24 | — | $495.1M |
| Q4 25 | — | $33.7M | ||
| Q3 25 | — | $71.7M | ||
| Q2 25 | — | $39.3M | ||
| Q1 25 | $101.7M | $20.7M | ||
| Q4 24 | — | $30.5M | ||
| Q3 24 | — | $19.4M | ||
| Q2 24 | — | $-153.0M | ||
| Q1 24 | — | $4.0M |
| Q4 25 | — | 9.9% | ||
| Q3 25 | — | 13.8% | ||
| Q2 25 | — | 12.8% | ||
| Q1 25 | 44.6% | 7.0% | ||
| Q4 24 | — | 7.8% | ||
| Q3 24 | — | 6.6% | ||
| Q2 24 | — | -31.3% | ||
| Q1 24 | — | 3.2% |
| Q4 25 | — | 6.8% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | — | 8.4% | ||
| Q1 25 | 21.2% | 4.5% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | — | 3.8% | ||
| Q2 24 | — | -30.3% | ||
| Q1 24 | — | 0.8% |
| Q4 25 | — | $0.40 | ||
| Q3 25 | — | $0.84 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.24 | ||
| Q4 24 | — | $0.37 | ||
| Q3 24 | — | $0.23 | ||
| Q2 24 | — | $-1.84 | ||
| Q1 24 | — | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $745.0M | $375.2M |
| Total DebtLower is stronger | — | $570.5M |
| Stockholders' EquityBook value | — | $865.9M |
| Total Assets | $3.4B | $2.2B |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $375.2M | ||
| Q3 25 | — | $340.1M | ||
| Q2 25 | — | $224.7M | ||
| Q1 25 | $745.0M | $99.0M | ||
| Q4 24 | — | $229.9M | ||
| Q3 24 | — | $103.8M | ||
| Q2 24 | — | $19.4M | ||
| Q1 24 | — | $8.0M |
| Q4 25 | — | $570.5M | ||
| Q3 25 | — | $577.2M | ||
| Q2 25 | — | $583.9M | ||
| Q1 25 | — | $590.5M | ||
| Q4 24 | — | $597.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $865.9M | ||
| Q3 25 | — | $890.7M | ||
| Q2 25 | — | $833.8M | ||
| Q1 25 | — | $789.2M | ||
| Q4 24 | — | $764.9M | ||
| Q3 24 | — | $732.5M | ||
| Q2 24 | — | $706.5M | ||
| Q1 24 | — | $856.2M |
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | $3.4B | $2.0B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $72.0M | $114.1M |
| Free Cash FlowOCF − Capex | $70.6M | — |
| FCF MarginFCF / Revenue | 14.7% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 0.71× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $114.1M | ||
| Q3 25 | — | $137.3M | ||
| Q2 25 | — | $137.2M | ||
| Q1 25 | $72.0M | $-117.5M | ||
| Q4 24 | — | $133.0M | ||
| Q3 24 | — | $91.8M | ||
| Q2 24 | — | $107.0M | ||
| Q1 24 | — | $-125.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $70.6M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 14.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 3.39× | ||
| Q3 25 | — | 1.91× | ||
| Q2 25 | — | 3.49× | ||
| Q1 25 | 0.71× | -5.66× | ||
| Q4 24 | — | 4.36× | ||
| Q3 24 | — | 4.72× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FINV
Segment breakdown not available.
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
